OKYO Pharma Ltd 6-K, filed Aug 19, 2022
OKYO Pharma Ltd (OKYO)
About this 6-K
OKYO Pharma Ltd filed this 6-K on August 19, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
August 2022
Commission File Number: 001-41386
OKYO Pharma LTD
(Exact Name of Registrant as Specified in Its Charter)
9th Floor
107 Cheapside
London
EC2V 6DN
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On August 19, 2022, OKYO Pharma LTD (the “Company”) issued a news service announcement in the United Kingdom issuing the Notice of AGM.
The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| OKYO Pharma LTD | ||
| Date: August 19, 2022 | By: | /s/ Gary Jacob |
| Name: | Gary Jacob | |
| Title: | Chief Executive Officer | |
| 3 |
EXHIBIT INDEX
| Exhibit
No. |
Description | |
| 99.1 | News Service Announcement, dated August 19, 2022 |
Exhibit 99.1
19 August 2022
OKYO Pharma Limited
(“OKYO” or the “Company”)
Notice of Annual General Meeting
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing an innovative approach to dry eye care and ocular pain, is pleased to announce that it will hold its annual general meeting (“AGM”) on 7 September 2022 at 12.00 midday.
A notice of AGM, together with a form of proxy will be posted to shareholders today. The notice of AGM will shortly also be available on the Company’s website, www.okyopharma.com. As previously advised, the annual report and accounts for the Company can also be found at www.okyopharma.com.
All voting on the resolutions at the AGM will be conducted on a poll, which means that Shareholders should either submit their proxy online or by post to the Company’s registrar, Computershare Investor Services (Guernsey) Limited, c/o The Pavilions, Bridgwater Road, Bristol BS99 6ZY, as soon as possible, and, in any event, so as to arrive by no later than 12.00 midday on 5 September 2022.
We ask that, where possible, questions which shareholders wish to raise be submitted to info@okyopharma.com in advance.
About OKYO Pharma Limited
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a life sciences company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange plc and to Nasdaq. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.
Enquiries:
| OKYO Pharma Limited | Gary S. Jacob, | +44 (0)20 7495 2379 | ||
| Chief Executive Officer | ||||
| Gabriele Cerrone, | ||||
| Non-Executive Chairman | ||||
| Optiva Securities Limited (Broker) | Robert Emmet | +44 (0)20 3981 4173 |
For further information, please visit the Company’s website at www.okyopharma.com.